John V. Soden
Cain Brothers Experience
John Soden is a Managing Director focused on Medical Technologies, including medical devices and device-related independent service organizations (ISOs), life science tools/reagents, diagnostic products and lab services. He is also the Head of Mergers & Acquisitions at Cain Brothers. John joined the firm in early 2016. He has 27 years of investment banking experience, primarily focused on private and public company M&A. His recent advisory transactions include the sale of Generate Life Sciences to CooperCompanies ($1.6bn), Generate Life Sciences’ acquisition of Cell Care Group, California Cryobank’s sale to GI Partners and its simultaneous merger with Cord Blood Registry, Arlington Capital Partners’ acquisition of Millstone Medical Outsourcing, the sale of Probo Medical to Avista Capital Partners, the sale of Northfield Medical to Agiliti Health ($475mm), Linden Capital Partners and Audax Private Equity’s acquisition of StatLab Medical Products, the sale of Advanced Instruments to Patricia Industries ($780mm), Patricia Industries’ acquisition of Sarnova from Water Street ($903mm), Blackstone’s investment in Sema4, and the sale of SeraCare Life Sciences to LGC. His recent capital raising transactions include public equity offerings for Agiliti Health, Codex DNA, LeMaitre Vascular, Maravai LifeSciences, Recursion, Sotera Health, and Stevanato Group.
Previously, John was a Managing Director & Head of Medical Technologies at Houlihan Lokey for approximately seven years. His transactions immediately prior to joining Cain Brothers included the sales of Hygiena to Warburg Pincus, Galil Medical to BTG Plc, CORPAK MedSystems (owned by Linden) to Halyard Health ($174mm), Cord Blood Registry (owned by GTCR) to AMAG Pharmaceuticals ($700mm), Ivera Medical to 3M, Integrated Medical Systems (IMS) to Steris ($175mm), and Angiotech Pharmaceutical’s Interventional business to Argon Medical Devices/Roundtable ($362mm). Notable restructuring experience included creditor representations with respect to Ameritox and Angiotech Pharmaceuticals.
John earned a BA in Economics (with Honors) from Northwestern University.